

Amendments to the Specification:

Please replace paragraph [0026] on page 8 with the following:

To increase immunogenicity, this invention provides vaccines in which both epitopes are fused to create a single peptide. The initial fusion peptide sequence to be evaluated contained the T_H epitope PADRE and the pp65₄₉₅₋₅₀₃ CTL epitope, referred to as K25V in Table I. Standard algorithms suggest that the significant hydrophobicity of K25V may enhance membrane association and entry into cellular protein degradation pathways. See Tsunoda et al., *Vaccine* ~~17~~675-685 17:675-685, 1999.